GISSI: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
{{SIB}} | {{SIB}} | ||
[[Category: Research groups]] | |||
[[Category: Medical research]] | |||
[[Category: Research]] | |||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 16:34, 8 May 2009
|
WikiDoc Resources for GISSI |
|
Articles |
|---|
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on GISSI at Clinical Trials.gov Clinical Trials on GISSI at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on GISSI
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating GISSI Risk calculators and risk factors for GISSI
|
|
Healthcare Provider Resources |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) (Italian group for the study of the survival of Myocardial Infarction) is an influential cardiology research group founded as a collaboration between two Italian organisations – the Mario Negri Institute and the Associazione Nazionale dei Medici Cardiologi Ospedalieri (ANMCO).[1] The trials carried out by GISSI have "obtained wide recognition in the international world of cardiology and are considered a methodological landmark"[1]. Four large-scale clinical trials over the past 20 years (GISSI 1[2][3], GISSI 2[4][5], GISSI 3[6], GISSI Prevention[7]) have involved more than 60,000 patients with acute myocardial infarction (AMI).[1]
References
- ↑ 1.0 1.1 1.2 http://www.gissi.org/EngIntro/T_Intro_ENG.php
- ↑ "Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)". Lancet. 1 (8478): 397–402. 1986. PMID 2868337.
- ↑ "Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI)". Lancet. 2 (8564): 871–4. 1987. PMID 2889079.
- ↑ "GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico". Lancet. 336 (8707): 65–71. 1990. PMID 1975321.
- ↑ "In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group". Lancet. 336 (8707): 71–5. 1990. PMID 1975322.
- ↑ "GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico". Lancet. 343 (8906): 1115–22. 1994. PMID 7910229.
- ↑ "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico". Lancet. 354 (9177): 447–55. 1999. PMID 10465168.
Further reading
- Article on olive oil and heart disease - mentions the GSSI Prevention study